The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. (ox.ac.uk)
METHODS: In this international, multicentre, randomised, open-treatment trial, patients were allocated to 0·9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA) or to control. (ox.ac.uk)
His main achievement has been his role in the development of tissue-type plasminogen activator (t-PA) from a laboratory concept to a life-saving drug for dissolving blood clots causing acute myocardial infarction or acute ischemic stroke. (wikipedia.org)
2 - 5 Acute ICA occlusions are more resistant than MCA occlusions to administration of intravenous tissue plasminogen activator (tPA). (ajnr.org)
She received intravenous recombinant tissue plasminogen activator (rt-PA) 2.5 hoursafter stroke onset, without subsequent improvement. (hindawi.com)
Intravenous (IV) thrombolysis with the recombinant tissue plasminogen activator (rtPA) alteplase significantly increases the probability of excellent recovery, but dosage and administration remain unchanged since 1995. (gla.ac.uk)
Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke. (bmj.com)
We randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activator [t-PA], mechanical clot disruption or retrieval, or a combination of these approaches) or intravenous t-PA. (nih.gov)
BACKGROUND: Intravenous recombinant tissue plasminogen activator (rtPA) is approved in Europe for use in patients with acute ischaemic stroke who meet strictly defined criteria. (lancs.ac.uk)
Tissue plasminogen activator (abbreviated tPA or PLAT ) is a protein involved in the breakdown of blood clots . (wikidoc.org)
The central goal of stroke therapy is the prompt reperfusion of occluded blood vessels to minimise tissue death, with administration of "thrombolysis" (intravenous recombinant tissue-type plasminogen activator, rtPA) - the only clinically approved drug available to stroke patients. (hri.org.au)
Importance:Earlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. (duke.edu)
2 3 Performance measurement of an acute stroke service can be evaluated based on the time from patient arrival at the hospital to the time of alteplase (tissue plasminogen activator (tPA)) administration or door-to-needle time (DTN). (bmj.com)
While intravenous administration of tissue plasminogen activator (tPA) remains the only FDA-approved treatment modality for acute ischemic stroke, many patients do not meet the criteria for intravenous tPA and are offered intra-arterial therapy. (bmj.com)
Since its approval in 1995, the administration of systemic intravenous tissue plasminogen activator (tPA) is the only FDA-approved treatment modality for acute ischemic stroke, 1 , 2 despite rapid advances in thrombectomy devices. (bmj.com)
Until recently, intravenous recombinant tissue plasminogen activator was the only proven effective treatment for acute stroke. (bmj.com)
Systemic thrombolysis with recombinant tissue plasminogen activator is the "gold standard" of reperfusion therapy, having the maximum level of evidence in European and North American guidelines for the treatment of patients with acute ischemic stroke (IS). (annaly-nevrologii.com)
The study included 396 patients with IS, of whom 196 patients underwent systemic thrombolysis with recombinant tissue plasminogen activator and 200 patients formed the control group. (annaly-nevrologii.com)
In a recent pooled analysis of randomized clinical trials (RCTs), intravenous tissue plasminogen activator (TPA) improves the outcome in patients aged ≥80 years. (j-stroke.org)
However, very elderly patients were excluded from or substantially under-represented in earlier intravenous tissue-plasminogen activator (TPA) trials [ 7 - 11 ]. (j-stroke.org)
Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed. (nih.gov)
Albers GWBates VEClark WMBell RVerro PHamilton SA Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment With Alteplase to Reverse Stroke (STARS) study. (jamanetwork.com)
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. (jamanetwork.com)
Alteplase4
Of 600 stroke patients receiving intravenous rt-PA using 0.6 mg/kg alteplase who were enrolled in a multicenter observational study in Japan, 4 patients (3 men, 64-77 years old) on maintenance HD were studied. (karger.com)
Based on the results of these studies, the Food and Drug Administration (FDA) approved the use of intravenous alteplase for the treatment of acute ischemic stroke when given within 3 hours of stroke symptom onset. (jointcommission.org)
Time to treatment with intravenous alteplase and outcome in stroke. (jamanetwork.com)
2019 May 9;380(19):1795-1803 Editorial: Image-Guided Intravenous Alteplase for Stroke - Shattering a Time Window. (emottawablog.com)
Ischemic8
The Ministry of Public Health and the National Health Security Office (NHSO) had accepted the use of intravenous thrombolysis as the standard treatment of acute ischemic stroke in 2008. (springer.com)
In patients with ischemic stroke, endovascular treatment results in a higher rate of recanalization of the affected cerebral artery than systemic intravenous thrombolytic therapy. (nih.gov)
The results of this trial in patients with acute ischemic stroke indicate that endovascular therapy is not superior to standard treatment with intravenous t-PA. (nih.gov)
However, the restrictive time window after symptom onset (up to 3-4.5 h) and sociocultural and geographical barriers to accessing rapid care results in only a small minority of patients with ischemic stroke receiving treatment with intravenous tPA. (bmj.com)
Uyttenboogaart MKoch MWKoopman KVroomen PCDe Keyser JLuijckx GJ Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. (jamanetwork.com)
Despite the extensive attempts in developing ischemic stroke treatments, only intravenous thrombolysis and endovascular thrombectomy have hitherto been shown to be effective in clinical settings. (explorationpub.com)
Ischemic stroke activates components of innate and/or adaptive immunity and induces brain inflammatory responses, which besides removing damaged tissue exacerbate ischemic brain injury [ 3 , 4 ]. (explorationpub.com)
Infusion5
The following parameters were recorded at baseline, after intravenous infusion of 500 mL of fluid load (colloid), 15 minutes and 150 minutes during LBPP application and 10 minutes after gravity suit deflation: right arm mobility, blood pressure, heart rate, systolic and diastolic velocities recorded on both MCAs and resistance index (RI) recorded on both common carotids arteries (CCAs). (hindawi.com)
6 , 10 , 11 The PROACT II study was a randomized trial of intra-arterial infusion of recombinant prourokinase (r-proUK) versus placebo (heparinized saline) in patients with angiographically documented proximal middle cerebral artery occlusion. (bmj.com)
12 Bang and colleagues reported the safety and feasibility of intravenous infusion of autologous mesenchymal stem cells (MSCs) with no reported adverse effects in five patients treated with intravenous MSCs. (bmj.com)
Thus, even a small insulin-like effect of IGF-I could be more important than that of insulin itself, were it not for the IGFBPs that control the availability and activity of IGF-I. In fact, intravenous infusion of recombinant human IGF-I (rhIGF-I) can induce hypoglycemia, especially in the IGFBP3 deficient state. (medscape.com)
BT-ON014 trade name] intravenous formulation is not intended for subcutaneous administration and should be administered via an intravenous infusion only. (who.int)
Thrombolysis in acute1
Intravenous thrombolysis in acute myocardial infarction. (medscape.com)
The assay for B. procyonis antibody, an immunoblot test using the recombinant antigen rBpRAG1, is specific and sensitive but cannot differentiate between current or previous infection or exposure ( 1 ). (cdc.gov)
Proteins1
Overall, our results demonstrate that EVs from cells overexpressing lysosomal enzymes act as natural protein delivery systems, improving the activity and the efficacy of the recombinant proteins and facilitating their access to organs neglected by conventional enzyme replacement therapies. (ibecbarcelona.eu)
Intra-arterial3
Although recent trials have failed to show a benefit over intravenous tPA of intra-arterial intervention using available devices, 8 , 9 patients outside the intravenous tPA window are still considered candidates for intra-arterial procedures. (bmj.com)
DiR-labelled EVs were localized in brain parenchyma 1 h after intra-arterial (internal carotid artery) or intravenous (tail vein) administrations. (ibecbarcelona.eu)
To determine the clinical efficacy and safety of intra-arterial (IA) recombinant prourokinase (r-proUK) in patients with acute stroke of less than 6 hours' duration caused by middle cerebral artery (MCA) occlusion. (nih.gov)
Therapeutic1
Therapeutic agents can be introduced into the body by several routes of administration with each having specific advantages and disadvantages (see Table I). For many drugs, including biologics and anticancer agents, the traditional route of administration is intravenous (IV). (pharmtech.com)
Acute stroke1
ICA occlusion of intravenous thrombolysis trials in patients with acute stroke have been based on the CT exclusion of hemorrhage 9 and on CT parenchymal evaluation 10 , 11 but have not pursued the exact cause or the level of occlusion. (ajnr.org)
Endovascular1
A total of 181 patients were assigned to receive endovascular therapy, and 181 intravenous t-PA. (nih.gov)
Therapy2
As Postdoc she developed innovative in vivo AAV gene therapy approaches based on liver gene transfer or multi-tissue gene expression to target the multi-organ manifestations of Pompe disease, a LSD that presents with neuromuscular impairment. (stanford.edu)
Acquired forms of GH insensitivity include the rare GH1 mutation (in which GH inhibiting antibodies develop after a few months of replacement therapy with recombinant GH) and, far more commonly, malnutrition, hepatic disease, renal disease, and diabetes. (medscape.com)
Patients4
Over the years, an abundance of research and clinical data has supported the safe and efficacious use of intravenous tPA in all eligible patients. (johnshopkins.edu)
The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. (jamanetwork.com)
In the setting of clinical practice, intravenous TPA within 4.5 hours improved the functional outcome despite an increased risk of symptomatic intracranial hemorrhage in very elderly Korean patients. (j-stroke.org)
Although many countries have not formally approved the use of TPA for patients aged over 80 years, experienced centers have treated very elderly patients with intravenous TPA if eligible. (j-stroke.org)
Subcutaneous tissue2
During SC administration, a needle is inserted through the epidermal and dermal layers of the skin and into the fatty subcutaneous tissue. (pharmtech.com)
A new technique has been presented that results in an acceleration of delayed primary healing with full thickness skin and subcutaneous tissue coverage. (who.int)
Enzyme3
Using a recombinant DNA-derived hyaluronidase enzyme is an approach for possibly changing dosing regimens and bioavailability of several types of agents, including biologics. (pharmtech.com)
Likewise, EVs carrying GLA (EV-GLA) were rapidly uptaken and reached the lysosomes in cellular models of Fabry disease, restoring lysosomal functionality much more efficiently than the recombinant enzyme in clinical use. (ibecbarcelona.eu)
A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. (lookformedical.com)
Clinically1
Moreover, a single intravenous administration of EV-GLA was able to reduce globotriaosylceramide (Gb3) substrate levels in clinically relevant tissues, such kidneys and brain. (ibecbarcelona.eu)
Injections1
By intracarotid and intravenous injections into live mice, we showed that these basic VHHs are able to cross the BBB in vivo, diffuse into the brain tissue, penetrate into astrocytes, and specifically label GFAP. (open.ac.uk)
Glial2
Severe ischemia, which in the CNS would produce necrosis of the neurons and glial elements, results in an area of dead tissue termed an infarct. (vin.com)
Here, we used recombinant VHH directed against human glial fibrillary acidic protein (GFAP), a specific marker of astrocytes. (open.ac.uk)
In addition to these receptors, hybrid receptors consisting of a dimer from the IGF-I receptor paired with the insulin receptor, are ubiquitous and the respective expression of these receptors varies from tissue to tissue. (medscape.com)
Safety1
Using multivariable analysis and propensity score (PS)-matched analyses, we assessed the effectiveness and safety of intravenous TPA within 4.5 hours. (j-stroke.org)
Onset1
If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. (lookformedical.com)
Brain1
Following a stroke, immune responses and neuroinflammation persist throughout all phases of injury, from early tissue damage to late brain tissue remodeling [ 3 , 4 ]. (explorationpub.com)
Specific2
To analyze their ability to be used as a specific transporter, we then expressed a recombinant fusion protein VHH-green fluorescent protein (GFP). (open.ac.uk)
Combining antigen-specific and tissue-based assays optimizes PCA-1/anti-Yo testing. (bvsalud.org)